Here's Wouldn't Touch Tilray: A Cautious Investor Guide
Tilray’s pivot to CBD and alcohol sparks questions about profitability and risk. This guide cuts through the hype, of...
A zero-based budget assigns every dollar a job, helping low-income households direct funds toward essentials, debt payoff, and savings.
22,326 articlesTilray’s pivot to CBD and alcohol sparks questions about profitability and risk. This guide cuts through the hype, of...
Bitcoin edges toward the long-term holder cost basis as on-chain data flags growing risk of capitulation. Analysts wa...
Soleno's Q4 2025 earnings paint a picture of growth with new products and expanding margins. This guide breaks down t...
Bitcoin sits at a decisive channel mid-line, facing a choice between a sustained rebound toward higher targets or a r...
Mortgage rates have dropped to their lowest level since 2022, easing borrowing costs for buyers and signaling renewed...
A top institutional SOL holder remains committed despite a near-$1 billion unrealized loss, shaping a long-term Solan...
Stocks moved sharply in both directions on Tuesday as investors weighed the risk of broader conflict in the Middle Ea...
A sharp February move put Remitly Global in the spotlight. This article breaks down the catalysts behind the rally, t...
As stocks march unfolds, the electric vehicle sector presents both challenges and opportunities. Here are two underva...
A supply-driven oil shock could force the Fed to put off rate cuts, creating a liquidity squeeze that analysts say co...
Conflicts in the Persian Gulf threaten the region’s desalination network, risking drinking water supplies for million...
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...